Ahren Innovation Capital Research
Investment Thesis
Ahren Innovation Capital is a London-based deep tech and deep science investor. It backs transformational companies at the intersection of ground-breaking science and high-end technology that will penetrate or create massive markets. The firm says it takes asymmetric, considered risk in pursuit of superior rewards, and wants its capital to have a positive impact on the world. Its tagline is "Investing in Deep Technology to Create the Unimaginable."
Ahren was founded in 2017 by Alice Newcombe-Ellis, formerly of TPG Capital and Lansdowne Partners, together with a group of senior Cambridge scientists who serve as Founding and Science Partners. These include Nobel laureates Sir Venki Ramakrishnan and Sir Gregory Winter, as well as Sir Shankar Balasubramanian, Sir Steve Jackson, Lord Martin Rees, Professor Andy Parker and Professor Zoubin Ghahramani. The firm says technologies created by its scientific partners are worth more than $100BN combined today. The Science Partners take part in sourcing, in deep-tech diligence and in supporting portfolio companies.
Sector Focus
Ahren names four broad domains of interest:
- Brain & AI: machine learning, applied AI and AI hardware, for example AI21 Labs, Graphcore and Phaidra
- Genetics & Platform Technologies: therapeutics platforms, genomics, cell reprogramming and engineering biology, for example Bicycle Therapeutics, Mogrify, Cellarity and Constructive Bio
- Space & Robotics: robotics and automation, for example Ambi Robotics, Mentee Robotics and Micropsi Industries
- Efficient Energy: climate and energy technology, for example Heirloom, Sunfire and Velocys
It also invests in quantum technology (Nu Quantum, Zapata AI) and food technology (New Culture, Zoe).
Stage Focus
Ahren partners with founders at all stages, from pre-seed to pre-IPO. It will help build companies from scratch or provide capital and expertise to high-growth businesses. It describes its capital as both patient and active.
Check Size
Ahren does not publish a check size.
Lead Tendency
The firm has led and co-led rounds. It led the 2018 seed round in Mogrify and the $30M round in Cambridge Epigenetix, co-led the Series A in Adrestia with GSK, and has also participated in rounds led by others, such as Zya's Series A.
Recent Activity
Ahren says it is investing from its latest fund and has more than $400M in dry powder. Its first fund closed at more than $250M in July 2019. In November 2025 Cassidy Bio launched with Ahren as an investor. Constructive Bio raised a $58M Series A in September 2024. Mentee Robotics, an Ahren portfolio company, was acquired by Mobileye. Adrestia was acquired by Insmed in August 2023, Graphcore by SoftBank, and 6D.ai by Niantic. Bicycle Therapeutics went public.
Portfolio Highlights
- AI21 Labs, Ambi Robotics, Bitfount, Micropsi Industries and Phaidra in applied AI and robotics
- Bicycle Therapeutics (IPO), Adrestia (acquired by Insmed), Cellarity, Mogrify, Constructive Bio, Edifice Health, Ovo Labs, Rubedo Life Sciences and Zoe in life sciences
- Heirloom, Sunfire, Velocys and Switchback Systems in energy and engineering biology
- Nu Quantum and Zapata AI in quantum
Team
- Alice Newcombe-Ellis, Founding & General Partner
- Peter Baines, Venture Partner (formerly General Partner at Advent Venture Partners)
- Joanna Green, Partner (life sciences)
- Janusz Marecki, AI Partner (formerly Lead Scientist at DeepMind)
- Oliver Hedaux, Principal (applied AI, robotics, science and education)
- Anuj Nanwani, Principal (planet and efficient energy, quantum)
- Peter Lourensz, Chief Financial Officer
- Associates: Sabila Chilaeva, Vera Kunz and Phoebe Seltzer
- Founding Partners: Sir Shankar Balasubramanian, Zoubin Ghahramani, Sir Steve Jackson, Andy Parker, Sir Venki Ramakrishnan, Lord Martin Rees and Sir Gregory Winter
- Science Partner: Roberto Cipolla
- Advisor: David Novak, Co-President of Clayton Dubilier & Rice
Decision Process
Ahren operates as a partnership of investors and scientists. The investment team sources and leads deals, and Science Partners join deep-tech diligence. The firm does not publish its decision timeline.
Founder Preferences
Ahren looks for exceptional founders and teams with a big vision and science-led technology. It offers a commercial engine, unicorn-founder advisors and strategic LP partnerships that give portfolio companies access, expertise and sometimes customers. It says it acts with strong values and treats founders well.
Geographic Focus
Ahren is based in London and backs companies in Europe, Israel and North America. Many of its early companies came out of Cambridge and other UK research institutions.